Format
Sort by

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 105

1.

The inflammatory cytokine tumor necrosis factor-alpha generates an autocrine tumor-promoting network in epithelial ovarian cancer cells.

Kulbe H, Thompson R, Wilson JL, Robinson S, Hagemann T, Fatah R, Gould D, Ayhan A, Balkwill F.

Cancer Res. 2007 Jan 15;67(2):585-92.

2.

Ovarian cancer cell-derived migration inhibitory factor enhances tumor growth, progression, and angiogenesis.

Hagemann T, Robinson SC, Thompson RG, Charles K, Kulbe H, Balkwill FR.

Mol Cancer Ther. 2007 Jul;6(7):1993-2002.

3.

Expression and regulation of tumor necrosis factor alpha in normal and malignant ovarian epithelium.

Szlosarek PW, Grimshaw MJ, Kulbe H, Wilson JL, Wilbanks GD, Burke F, Balkwill FR.

Mol Cancer Ther. 2006 Feb;5(2):382-90.

4.

The inflammatory cytokine tumor necrosis factor-alpha regulates chemokine receptor expression on ovarian cancer cells.

Kulbe H, Hagemann T, Szlosarek PW, Balkwill FR, Wilson JL.

Cancer Res. 2005 Nov 15;65(22):10355-62.

5.
6.

Multiple actions of the chemokine CXCL12 on epithelial tumor cells in human ovarian cancer.

Scotton CJ, Wilson JL, Scott K, Stamp G, Wilbanks GD, Fricker S, Bridger G, Balkwill FR.

Cancer Res. 2002 Oct 15;62(20):5930-8.

8.

Breaking the 'harmony' of TNF-α signaling for cancer treatment.

Sasi SP, Yan X, Enderling H, Park D, Gilbert HY, Curry C, Coleman C, Hlatky L, Qin G, Kishore R, Goukassian DA.

Oncogene. 2012 Sep 13;31(37):4117-27. doi: 10.1038/onc.2011.567.

9.

CXCL12 and vascular endothelial growth factor synergistically induce neoangiogenesis in human ovarian cancers.

Kryczek I, Lange A, Mottram P, Alvarez X, Cheng P, Hogan M, Moons L, Wei S, Zou L, Machelon V, Emilie D, Terrassa M, Lackner A, Curiel TJ, Carmeliet P, Zou W.

Cancer Res. 2005 Jan 15;65(2):465-72.

10.
11.

A dynamic inflammatory cytokine network in the human ovarian cancer microenvironment.

Kulbe H, Chakravarty P, Leinster DA, Charles KA, Kwong J, Thompson RG, Coward JI, Schioppa T, Robinson SC, Gallagher WM, Galletta L; Australian Ovarian Cancer Study Group., Salako MA, Smyth JF, Hagemann T, Brennan DJ, Bowtell DD, Balkwill FR.

Cancer Res. 2012 Jan 1;72(1):66-75. doi: 10.1158/0008-5472.CAN-11-2178.

12.

Blockade of the stromal cell-derived factor-1/CXCR4 axis attenuates in vivo tumor growth by inhibiting angiogenesis in a vascular endothelial growth factor-independent manner.

Guleng B, Tateishi K, Ohta M, Kanai F, Jazag A, Ijichi H, Tanaka Y, Washida M, Morikane K, Fukushima Y, Yamori T, Tsuruo T, Kawabe T, Miyagishi M, Taira K, Sata M, Omata M.

Cancer Res. 2005 Jul 1;65(13):5864-71.

14.

Role of high expression levels of CXCR4 in tumor growth, vascularization, and metastasis.

Darash-Yahana M, Pikarsky E, Abramovitch R, Zeira E, Pal B, Karplus R, Beider K, Avniel S, Kasem S, Galun E, Peled A.

FASEB J. 2004 Aug;18(11):1240-2.

15.

Lysophosphatidic acid receptors determine tumorigenicity and aggressiveness of ovarian cancer cells.

Yu S, Murph MM, Lu Y, Liu S, Hall HS, Liu J, Stephens C, Fang X, Mills GB.

J Natl Cancer Inst. 2008 Nov 19;100(22):1630-42. doi: 10.1093/jnci/djn378.

16.

Epithelial cancer cell migration: a role for chemokine receptors?

Scotton CJ, Wilson JL, Milliken D, Stamp G, Balkwill FR.

Cancer Res. 2001 Jul 1;61(13):4961-5.

17.
18.

Inhibition of the inflammatory cytokine TNF-α increases adenovirus activity in ovarian cancer via modulation of cIAP1/2 expression.

Salako MA, Kulbe H, Ingemarsdotter CK, Pirlo KJ, Williams SL, Lockley M, Balkwill FR, McNeish IA.

Mol Ther. 2011 Mar;19(3):490-9. doi: 10.1038/mt.2010.247.

19.

Interleukin-1β promotes ovarian tumorigenesis through a p53/NF-κB-mediated inflammatory response in stromal fibroblasts.

Schauer IG, Zhang J, Xing Z, Guo X, Mercado-Uribe I, Sood AK, Huang P, Liu J.

Neoplasia. 2013 Apr;15(4):409-20.

Items per page

Supplemental Content

Support Center